. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Leukemia. 2014 Apr 15;28(11):2229–2234. doi: 10.1038/leu.2014.140

Table 1.

Characteristics and details of studies used for gene expression profile-based response prediction.

	IFM I	IFM II	HOVON	Mulligan et al.
Study	IFM 2005^#	IFM 2005^#	HOVON 65 MM / GMMG HD4^$	APEX / SUMMIT
Number of Samples	136	67	282	162
Platform	Affymetrix Exon 1.0 ST array	Affymetrix Exon 1.0 ST array	Affymetrix U133 Plus 2.0 array	Affymetrix U133 Plus 2.0 array
Patient Population	Newly-diagnosed	Newly-diagnosed	Newly-diagnosed	Relapsed
Treatment Protocol	VAD, ASCT	Bortezomib, ASCT	VAD/PAD, ASCT	Bortezomib
Time of Response Measurement	Post-transplant	Post-Induction	Post-transplant	Post Salvage therapy
Complete response	44 (32%)	24 (36 % %)	76 (27 %)	73 (43%)^∞

: NCBI GEO accession IDs: IFM I: GSE39754, IFM II: GSE55145.

: Broyl A, et al. Blood 2010

^∞

: Includes patients with partial response; 13 patients with CR and 60 with PR.